The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site.

All material subject to strictly enforced copyright laws. © 2020 Euromoney, a part of the Euromoney Institutional Investor PLC.

Daniel Vasella: Doctor Vasella revives Novartis

Daniel Vasella has had a tough time as chief executive of life sciences company Novartis, with a collapse in its agribusiness, management turmoil in pharmaceuticals and weak performance in the US. But he's restructured the company and now hopes new drugs can deliver growth.


On March 7 1996, the then largest corporate merger in any industry was announced. Novartis was formed by the merger of Swiss drugs and chemicals leaders Sandoz and Ciba-Geigy in a deal worth Sfr75 billion ($41.2 billion). The new company held a 4.4% share of the world pharmaceuticals market, just behind GlaxoWellcome's 4.7%, and was twice as large as its nearest rival in agrichemicals.

This momentous deal had been set in train on November 30 1995 when Marc Moret, chairman of Sandoz, crossed the Rhine in Basel, Switzerland, to meet Ciba-Geigy's chairman, Alex Krauer.

Take out a complimentary trial

Take out a 7 day trial to gain unlimited access to and analysis and receive expertly-curated updates direct to your inbox.


Already a user?

Login now


We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree